INTRODUCTION
The field of perioperative medicine continues to mature as evidenced by the growing number of high-quality articles published each year. This is encouraging given the increasingly complex patient population that routinely undergoes major surgery. Furthermore, as surgeons have become more subspecialized, there is increased reliance on the generalist to perform consultative medicine for the preoperative patient, as well as co-manage patients throughout the hospitalization.
METHODS
This article is a summary of the Update in Perioperative Medicine session presented at the 34th Annual Meeting of the Society of General Internal Medicine (SGIM). From May 2010 to April 2011, the perioperative and consultative medicine interest group gathered articles that contributed to the field of perioperative medicine and impacted daily practice for clinicians who provide care for the surgical patient. The interest group discussed these articles and ranked them in order of clinical relevance, then categorized them into the following: consultative medicine, perioperative cardiac medicine, perioperative pulmonary medicine, perioperative medication management, and venous thromboembolism.
RESULTS/CONCLUSIONS Consultative Medicine
Outcomes and Processes of Care Related to Preoperative Medical Consultation. Wijeysundera DN, Austin PC, Beattie WS, et al. Arch Intern Med 2010;170:1365-1374. Surgeons request preoperative medical consultations for various reasons to improve management and outcomes; however, the impact of these consults is unclear. This population-based cohort study sought to determine whether preoperative medical consultation was associated with reduced mortality or length of stay after major elective noncardiac surgery.
The Ontario Health Insurance Plan (OHIP) claims-based definition of preoperative consultation includes those performed by an internist, cardiologist, endocrinologist, or geriatrician within 4 months before surgery. Of 269,866 patients in the cohort, 38.8% had consultations. An analysis of a propensity score-matched cohort of 191,852 patients found that consultation was associated with an increased 30-day mortality (RR 1.16; 95% CI 1.07-1.25; NNH 516), 1-year mortality (1.08; 95% CI 1.04-1.12; NNH 227), and mean hospital stay (9.07 vs 8.39 days; difference 0.67 days; 95% CI 0.59-0.76; p<0.001). These findings were consistent across various subgroups and persisted for sensitivity analyses that adjusted for potential confounders. Preoperative consultation was also associated with changes in care that included increases in preoperative testing, beta-blockers or statin use, cardiac interventions, and postoperative use of mechanical ventilation and monitored beds.
Patients referred for consultation had more comorbid illnesses and were at increased risk for adverse outcomes. Limitations of this observational study, which could negate the small increase in mortality, include unmatched cases, the potential for residual confounding, the exclusion of cancelled surgeries, differences between consultants (generalist vs specialist), and duration of postoperative follow-up.
Implications for Clinical Practice. Other smaller single-center studies have shown that preoperative medical consultation shortly before surgery is associated with increased length of hospital stay and cost with no difference in process of care (betablocker use). 1 Previous studies of outpatient consultation have demonstrated a reduction in last minute surgical delays but no effect on hospital stay or postoperative complication rates. 2 Compliance with consultants' recommendations and the degree of perioperative comanagement may vary considerably. Due to the previously noted limitations, it is unlikely that preoperative consultations actually increase mortality, although more selective consultation may be warranted. The practice of obtaining preoperative consultations, particularly for patients felt to be at increased risk, should not change until multicenter studies employing rigorous qualitative and quantitative research methods better define mechanisms by which consultation influences outcome and identify which interventions improve outcomes. Four cardiac biomarker or enzyme assays were measured within 3 days of surgery. The definition of perioperative MI included either autopsy findings of acute MI or an elevated level of a cardiac biomarker or enzyme, and at least 1 of the following defining features: ischemic symptoms, new pathologic Q waves, ischemic changes on electrocardiography, coronary artery intervention, or cardiac imaging evidence of MI. A month after random assignment in the POISE trial, a total of 415 patients (5.0%) had a perioperative MI. Most MIs (74.1%) occurred within 48 h of surgery; 65.3% of patients did not experience ischemic symptoms. The 30-day mortality rate was 11.6% among patients who had a perioperative MI and 2.2% among those who did not (P<0.001). Among patients with a perioperative MI, mortality rates were elevated and did not differ for those with and without ischemic symptoms (9.7% vs 12.5%, respectively). Independent predictors of perioperative MI included a 10-beats/min increase in baseline heart rate (OR 1.29; 95% CI 1.13-1.50) and serious bleeding (OR 3.62; 95% CI 2.07-6.36). Emergency or urgent surgery was also associated with perioperative MI (OR 2.94; 95% CI 1.65-5.26). The authors concluded that clinicians should routinely measure postoperative troponin levels for high-risk patients to detect asymptomatic MIs, as the outcomes are similar to those of symptomatic MIs.
Perioperative Cardiac Medicine
Implications for Clinical Practice. Most patients who sustain a perioperative MI do not experience ischemic symptoms. Both asymptomatic and symptomatic perioperative MI confers increased rates of 30-day mortality. Therefore, routine monitoring of cardiac biomarkers in high-risk patients is essential after surgery. The highest risk for death after perioperative MI was in the first 48 h; this was true regardless of whether the patient experiences ischemic symptoms. Whether intervention to treat asymptomatic MIs after surgery improves outcomes is unknown based on the study results. Randomized, controlled trials to establish effective treatments for perioperative MI are urgently needed. Until such trials are conducted, beneficial interventions for secondary cardiac prevention (such as a statins, beta blockers, and angiotensin-converting enzyme inhibitors) seem reasonable. surgery at a single center in The Netherlands. Systolic dysfunction was defined as an ejection fraction of less than 50%, both with and without accompanying diastolic dysfunction. The study endpoints were 30-day cardiovascular events (defined as myocardial ischemia, infarction, and mortality) and long-term cardiovascular mortality. The authors performed a multivariate regression analysis to evaluate the relation between LV function and the study endpoints.
LV dysfunction was present in half of all patients; 80% of these patients were asymptomatic. The 30-day CV event rate was highest in patients with symptomatic heart failure (49%), followed by those with asymptomatic systolic LV dysfunction (23%), asymptomatic diastolic LV dysfunction (18%), and normal LV function (10%). These differences were statistically significant; a similar trend existed for long-term CV mortality ( Fig. 1 ). Adjusting for medication use (such as beta-blockers and statins) did not change the prognostic value of LV dysfunction.
Implications for Clinical Practice. The widely adopted Revised Cardiac Risk Index (RCRI) includes stable congestive heart failure as an independent clinical predictor of perioperative CV risk. 5 This study suggests that detecting preclinical LV dysfunction may also be of value in vascular surgery patients. The presence of asymptomatic LV dysfunction may alter perioperative management (i.e., optimization of cardiac medications, judicious fluid management, and intensive postoperative surveillance) and influence operative decisions such as favoring an endovascular approach over an open procedure when possible. Although this study adds important information to the perioperative literature, it is too early to recommend routine preoperative echocardiography for high-risk patients. A study by Xu-Cai et al. demonstrated that patients with clinically stable heart failure did not have increased mortality rates in association with elective major noncardiac surgery. 6 Furthermore, the recently published guidelines on appropriate use criteria for echocardiography state it is "inappropriate" to assess ventricular function in patients without signs or symptoms of CV disease in the preoperative setting. The impact of pulmonary hypertension on perioperative outcomes is not well established. In this study, the authors used the National Inpatient Sample (NIS), from a 20% stratified sample of US hospitals, to identify all patients with pulmonary hypertension undergoing knee (TKA) or hip (THA) replacement surgery from 1998-2006. Subjects were eligible if they had ICD-9 codes for primary total hip or knee arthroplasty, and also a code for primary pulmonary hypertension or chronic pulmonary heart disease. The primary outcome measure was mortality; secondary outcomes were pulmonary embolus (PE), deep venous thrombosis (DVT), and adult respiratory distress syndrome (ARDS). The authors identified a sample without pulmonary hypertension that was matched for age, Deyo comorbidity index, gender, race, hospital size and location, teaching hospital status, and admission type. A multivariable regression analysis was performed to adjust for potential confounding factors.
The authors identified 3,302 patients with pulmonary hypertension for whom they could identify a matched sample (THA = 1,245, THR = 2,057). Patients were well matched according to the above demographic variables. For patients undergoing THA, the unadjusted odds ratio for mortality was 3.72 (95% CI 2.13-6.39, rate 2.41% vs 0.65%) for patients with pulmonary hypertension. The corresponding result for TKA was OR 4.55 (95% CI 0.91 2.16-9.39, rates 0.91% vs 0.2%). Adjusted odds ratios were similar. Adjusted odds ratios for ARDS, PE, and DVT were 4.86 (95% CI 3.60-6.57), 4.63 (95% CI 3.32-6.45), and 2.35 (95% CI 1.92-2.88), respectively, for THA. Results were similar for patients undergoing TKA. Independent predictors of mortality were pulmonary hypertension, advanced age, male gender, Deyo comorbidity index, and emergency surgery. Mortality rates were approximately three times higher for patients with primary pulmonary hypertension than for those with secondary pulmonary hypertension.
Implications for Clinical Practice. This is by far the largest study of the importance of pulmonary hypertension as a risk factor for perioperative morbidity and mortality. Three previous studies 8-10 contained a total of 236 patients. Mortality rates among patients with pulmonary hypertension undergoing noncardiac surgery in these reports ranged from 7% to 10%. Important limitations of the study include the use of ICD-9 coding to identify cases (which may fail to capture all cases), the potential for disease misclassification, and lack of data on disease severity. Strengths of the study are the large number of subjects and the use of mortality as an outcome. It is unknown if clinically unapparent pulmonary hypertension carries the same risk or if we should screen for pulmonary hypertension in patients with risk factors for the disease before surgery. Finally, this study does not establish which interventions, if any, reduce this risk. Based on this study, clinicians should consider pulmonary hypertension, both primary and secondary, as an important patient-related predictor for mortality and venous thromboembolic complications. risk factors. The authors used an explicit set of definitions for PPC that included respiratory infection, respiratory failure, pleural effusion, atelectasis, pneumothorax, bronchospasm, and aspiration pneumonia. Thirty-three variables were entered into a multivariable analysis. A total of 242 pulmonary complications occurred in 123 patients (5.0% of all subjects). Respiratory failure was the most common complication (2.6%). Length of stay was substantially longer among patients who developed a PPC than among those who did not (12 vs 3 days). Ninety-day mortality was also significantly greater (24.4% vs 1.2%, p<0.001). Independent predictors of PPC after adjustment were advanced age, preoperative hypoxemia, recent respiratory infection, anemia, high-risk surgical site, prolonged surgery, and emergency surgery. The authors constructed a weighted multifactorial index ( Table 1 ) that performed well; the area under the receiver operating characteristic curve was 0.90 for the development subsample and 0.88 for the validation cohort. PPC rates in the validation sample were 1.6%, 13.3%, and 42.1% for low, intermediate, and high-risk scores.
Prediction of Postoperative Pulmonary Complications in a
Implications for Clinical Practice. This is the largest prospective study of PPC risk factors that used a structured instrument to capture potential factors in a uniform fashion. This study reconfirms factors identified in the 2006 American College of Physicians guideline including advanced age, high-risk surgical site, prolonged surgery, and emergency surgery.
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Novel factors are preoperative oxygen desaturation, preoperative anemia, and recent respiratory infection. When compared to the most robust existing multifactorial risk index for respiratory failure, from the NSQIP database, 12 overall PPC rates are higher in each group largely because of the inclusion of minor complications of minimal clinical significance (for example, new wheezing treated with bronchodilators). The index is, however, much simpler to use and has only 7 factors rather than 28 factors. The study reconfirms the morbidity and high mortality of PPC. While it may overestimate the risk of serious PPC, this study is an important advance in our ability to stratify PPC risk before surgery. It is an appropriate tool to guide decision-making and informed consent discussions with patients.
Perioperative Medication Management
Timing Exclusions included emergency surgery, preoperative bradycardia (<50 beats/min), and participation in previous beta-blocker trials. The primary outcomes were 30-day cardiovascular events (composite of myocardial ischemia or infarction, stroke, and mortality) and long-term mortality. Investigators stratified patients into three groups based on the duration of preoperative beta-blocker use: <1, >1 to 4, and >4 weeks before surgery. Bisoprolol was used in 70% of the patients. Median baseline heart rates (74, 70, and 66 beats/ min, respectively) were lower in patients whose treatment was initiated >1 week before surgery (p <0.001), but hsCRP was not significantly different. Treatment for >1-4 and >4 weeks before surgery was associated with a lower incidence of 30-day cardiac events (OR 0.46; 95% CI 0.27-0.76 and OR 0.46; 95% CI 0.29-0.79, respectively) and long-term mortality (HR 0.52; 95% CI 0.21-0.67 and HR 0.50; 95% CI 0.25-0.71) when compared to treatment initiated <1 week preoperatively (Table 2) for both high-risk and intermediate risk procedures.
Implications for Clinical Practice. This study demonstrated improved postoperative outcomes for patients who received beta-blockers for at least 1 week before surgery, presumably Risk score Of the 212 patients enrolled, 193 underwent surgery. The mean age was 67 years, and two thirds of the patients were female. The most common indications for furosemide were hypertension and edema; only 19% of patients received this medication for congestive heart failure. Intraoperative hypotension (defined as systolic blood pressure <90 mmHg or mean arterial pressure <35% from baselines, or use of a vasopressor agent) occurred in 49% in the furosemide group as compared to 52% in the placebo group [relative risk 0.95 (95% CI 0.72-1.24) p=0.78]. In addition, no significant differences were present for CV events, CHF, electrolytes, and renal function.
Implications for Clinical Practice. To our knowledge, this is the first randomized controlled trial to evaluate the safety of continuing a medication on the morning of surgery. It appears the feared risk of loop diuretics causing intraoperative hypotension is theoretical as no significant difference in blood pressure occurred. This trial consisted of a patient population undergoing a wide variety of surgeries and different anesthetic techniques. Although this study was adequately powered to detect significant differences in intraoperative blood pressure, the secondary endpoints should be interpreted with caution as it was underpowered to evaluate differences for these outcomes. Given these findings, physicians may choose to either hold or continue furosemide on the day of surgery without fear of causing an appreciable effect on intraoperative hemodynamics. More than half (57%) of the IVC filter patients who experienced death/permanent disability had a fatal pulmonary embolism or complications directly related to the IVC filter itself, including thrombosis of the vena cava or filter migration. The authors concluded that prophylactic IVC filters for gastric bypass surgery do not reduce the risk of pulmonary embolism and may lead to additional complications.
Venous Thromboembolism
The most important limitation of this study is potential selection bias. Although the authors used propensity score methods to minimize the risk of confounding, unknown variables (i.e., the presence of a thrombophilia) are not accounted for. Other limitations include a lack of statistical power to demonstrate significant harm associated with IVC filter use, no reported data on the type of IVC filters used, and the absence of long-term follow-up, which may underestimate the potential harm of IVC filters over time.
Implications for Clinical Practice. Routine use of prophylactic IVC filters for before gastric bypass surgery provides no clinical benefit and confers increased rates of major complications. Furthermore, among patients who receive prophylactic IVC filters, half of all cases of death or permanent disability were directly related to the device itself. Aside from their potential risks, IVC filters increase the cost of care. The authors concluded that excess costs attributable to preoperative IVC filter placement in bariatric surgery patients may total 250 million dollars in the US annually. Pending further study, clinicians should not recommend routine use of IVC filters before bariatric surgery. 
